Oasmia Pharmaceutical AB (Nasdaq: OASM) today announce that the company has signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea.
Technology and know-how are already transferred to Baxter and manufacturing is planned to commence within a short period of time.
Apealea will be manufactured at Baxter’s manufacturing site in Halle/Westfalen, Germany, one of the most advanced facilities for cytotoxic contract manufacturing in the world. Manufacturing at Oasmia’s own site in Uppsala is now shifted to focus on the company’s other products, Doxophos and Docecal.
‘This is an important step for Oasmia’s future growth and essential for our commercial success. We see this as an important step to accelerate the launch of Apealea and our other product candidates. Baxter is a very strong partner and enables us to meet the global demand of Apealea,’ says Julian Aleksov, Executive Chairman of Oasmia Pharmaceutical AB.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.